Notable new ophthalmology approvals
Xeomin (incobotulinumtoxinA) was approved as first-line treatment of blepharospasm.
Eylea (aflibercept intravitreal) is now approved for all stages of diabetic retinopathy.
Rocklatan (netarsudil/latanoprost) was approved for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Avaclyr (acyclovir ophthalmic) was approved as a new dosage administration route for herpes simplex virus (HSV-1 and HSV-2).
Medscape © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA Drug Approvals — 2019 Midyear Review - Medscape - Aug 09, 2019.